首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Medicine >Atorvastatin up-regulates TRIB3 independent of ATF4-CHOP pathway in atherosclerotic patients
【2h】

Atorvastatin up-regulates TRIB3 independent of ATF4-CHOP pathway in atherosclerotic patients

机译:阿托伐他汀独立于ATF4-CHOP途径上调动脉粥样硬化患者的TRIB3

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Macrophage apoptosis triggered by endoplasmic reticulum (ER) stress contributes much to atherosclerosis, especially plaque vulnerability. Activating transcription factor 4 (ATF4)-CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP)-Tribbles 3 (TRIB3) pathway is closely related to the ER stress. This study aimed to investigate the effect of atorvastatin on the ATF4-CHOP-TRIB3 pathway. Methods: Forty-seven patients were randomized into 80-mg and 20-mg atorvastatin group. Follow-up was performed at weeks 6 and 12, and complete blood chemistry, lipid assay and detection of 5 target genes (tumor protein 53, ATF4, C/EBP, CHOP and TRIB3) in monocytes/macrophages were conducted. Furthermore, the interaction between dosage and duration of therapy was evaluated. Results: After 12-week therapy, patients in both groups experienced significant reductions in ATF4 (P=0.038) and C/EBP (P=0.003) expressions. Tumor protein 53 (P=0.015) and TRIB3 (P=0.045) expressions increased markedly in 80-mg atorvastatin group. However, there was no significant difference in CHOP expression at three time-points and between atorvastatin groups. Moreover, there was no interaction between dosage and duration of therapy. Conclusions: Atorvastatin has an effect on ER stress through ATF4-CHOP pathway. Atorvastatin at a high dose is more likely to increase TRIB3 expression, but this warrants further investigation.
机译:背景:内质网应激触发的巨噬细胞凋亡在动脉粥样硬化,尤其是斑块易损性中起很大作用。激活转录因子4(ATF4)-CCAAT /增强子结合蛋白(C / EBP)同源蛋白(CHOP)-Tribbles 3(TRIB3)途径与内质网应激密切相关。本研究旨在研究阿托伐他汀对ATF4-CHOP-TRIB3途径的影响。方法:将47例患者随机分为80mg和20mg阿托伐他汀组。在第6和12周进行随访,并进行全血化学,脂质测定和单核细胞/巨噬细胞中5个靶基因(肿瘤蛋白53,ATF4,C / EBP,CHOP和TRIB3)的检测。此外,评估了剂量和治疗持续时间之间的相互作用。结果:经过12周的治疗,两组患者的ATF4(P = 0.038)和C / EBP(P = 0.003)表达均明显降低。在80mg阿托伐他汀组中,肿瘤蛋白53(P = 0.015)和TRIB3(P = 0.045)的表达明显增加。然而,在三个时间点以及阿托伐他汀组之间CHOP表达没有显着差异。而且,剂量和疗程之间没有相互作用。结论:阿托伐他汀通过ATF4-CHOP途径对内质网应激有影响。高剂量的阿托伐他汀更有可能增加TRIB3的表达,但这值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号